Ваша жизнь в ваших руках. Как понять, победить и предотвратить рак груди и яичников

cer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J Cancer, 46 (2), 293–298; Weber, C.J. and others, 1989. Gastrin-releasing peptide, calcitonin gene-related peptide, and calcitonin-like immu-no-reactivity in human breast cyst fluid and gastrin-releasing peptide-like immunoreactivity in human breast carcinoma cell lines. Surgery, (6), 1134–1139 (disc. 1139–1140).

28. Markwalder, R. and others, 1999. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Research, 59 (5), 1152–1159; Festuccia, C. and others, 1998. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int. J. Cancer, 75 (3); 418–431: Krongrad, A. and others, 1997. Endopeptidase 24.11 activity in the human prostate cancer cell lines LNCaP and PPC-1. Urological Research, 25 (2), 113–116; Jungwirth, A. and others, 1997. LHRH antagonist Cetrolix (SB-75) and bombesin-antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate, 32 (3), 164–172; Larran, J. and others, 1996. In vitro characterization of bombesin and calcitonin on the proliferation of PC3, DK145 and LNCaP cancer prostatic cell lines. International Journal of Developmental Biology, 1996 (Suppl. 1), 275S-276S; Aprickian, A.G. and others, 1996. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostatic cancer cells. Journal of Molecular Endocrinology, 16 (3), 297–306; Bologna, M. and others, 1989. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer, 63 (9), 1714–1720; Wasilenko, WJ. and others, 1996. Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int J Cancer, 68 (2), 259–264.

29. Takeyama, M. and others, 1989. Enzyme immunoassae of gastrin-releasing, peptide (GRP)-like immunoreactivity in milk. Int J Pept Protein Res, 34 (1), 70–74.

30. Ducroc, R. and others, 1995. Immunoreactive substance P and calcitonin-gene-related peptide (CGRP) in rat milk and in human milk and infant formula’s. Am J Clin Nutr, 62 (3), 554–558.

31. Lembeck, F. and others, 1979. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Arch Pharmacol, 310 (2), 175–183.

32. Khare, V K. and others, 1998. The neuropeptide/mast cell secretagogue substance F is expressed in cutaneous melano-cyticlesions. Journal of Cutaneous Pathology, 25 (1), 2-10.

33. Ducroc, R. and others, 1995. Immunoreactive substance P and calcitonin-gene-related peptide (CGRP) in rat milk and in human milk and infant formula’s. Am J Clin Nutr, 62 (3), 554–558.

34. Faulkner, A., 1998. Insulin-like growth factor 1 concentrations in milk and plasma after growth hormone treatment. Biochemical Society Transactions, 26 (4), 386; Silanikove, N. and others, 1998. Metabolic and productive response of dairy cows to increased ion supplementation at early lactation in warm weather. Journal of Dairy Research, 65 (4), 529–543; Ginjala, V. and others, 1998. Determination of transforming growth factor-beta 1 (TGF-beta 1) and insulin-like growth factor-1 (IGF-1) in bovine colostreum samples. Journal of Immunoassay, 19 (2–3), 195–207; Schober, D.A. and others, 1990. Perinatal expression of type 1 IGF receptors in porcine small intestine. Endocrinology, 126 (2), 1125–1132.

35. Rao, R.K. and others, 1998. Luminal stability of insulin-like growth factor-1 and -2 in developing rat gastrointestinal tract. Journal of Pediatric Gastroenterology and Nutrition, 26 (2), 179–185.